Non-Small Cell Lung Cancer - Angiogenesis and signal transduction inhibitors to expand market

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-04-05

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Non-small cell lung cancer comprises over 75% of all lung cancers. In 2006, more than 338,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the overall survival of NSCLC patients remains below 12 months.


Scope

  • Overview of NSCLC and the current treatment options, including profiles and analysis of existing drugs
  • Insightful analysis of clinical trial data for late-phase drugs in development for NSCLC
  • Future global sales of key pipeline drugs for NSCLC to 2015, including their clinical/research and commercial attractiveness
  • Datamonitor's assessment of the clinical and commercial potential of the drugs currently in development for NSCLC


    • Report Highlights
    Amgen's panitumumab will prove popular among physicians due to its favorable toxicity profile and EGFR target. With panitumumab seeking to gain initial approval in the first-line setting, Datamonitor believes the agent will rapidly gain ground on BMS/Merck KgGA's Erbitux, despite the latter's first-to-market advantage.

    Over the forecast period to 2015, Datamonitor believes Avastin will be the sole MTT to achieve blockbuster status within the NSCLC market. Avastin's 2015 sales of $1285m are forecast to eclipse those of Tarceva ($737m) and Erbitux ($696m). This is largely attributed to the size of Avastin's target population within the first-line setting.

    In attempting to avoid the fate of AstraZeneca's recently withdrawn drug Iressa, developers must allow for adequate maturation of trial data in order to explicitly demonstrate the clinical benefit of novel pipeline agents. The time/cost ratio of clinical development must be regularly reviewed to ensure the commercial success of innovative agents.


    Reasons to Purchase

  • Assess opportunities and risks in the NSCLC market by analyzing the clinical and commercial attractiveness of key agents
  • Evaluate the potential of your product in the NSCLC cancer market by examining key pipeline drugs' sales forecasts
  • Determine the commercial impact of new molecular-targeted agents entering the NSCLC market and their effects on the current treatment paradigms

    • Table of Contents

    Other users found this report page using the following search terms: nsclc non-small cell lung cancer angiogenesis nsclc cancer lung incidence cell pipeline small non sutent signal

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.